

## Special Issue

# Optimizing Drug Therapy and Developing Novel Therapeutic Interventions in Nephrology

### Message from the Guest Editors

Novel therapeutic agents have been widely used in the field of nephrology, primarily in immune-mediated glomerular diseases and renal transplantation and to a lesser extent in AKI, CKD, and inherited kidney diseases such as APDKD. Immunosuppressive agents are the mainstay of therapy; besides immunosuppressants, investigational agents that slow down fibrosis such as senolytic drugs, the vasopressin V2-receptor antagonist that delays cyst development in APDKD, and SGLT2 inhibitors (gliflozins) in DM type II have all been used with promising results. The purpose of this Special Issue is to place these agents into a context together with a brief discussion of unique features of their development and their use that will be of interest to many specialists of internal medicine.

---

### Guest Editors

Dr. Smaragdi Marinaki

Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National & Kapodistrian University of Athens, 11527 Athens, Greece

Dr. Sophia Lionaki

Department of Nephrology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece

---

### Deadline for manuscript submissions

closed (1 October 2021)



## Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/56709](https://mdpi.com/si/56709)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://mdpi.com/journal/)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)



## About the Journal

### Message from the Editorial Board

*Journal of Clinical Medicine* (ISSN 2077-0383) is an international, peer-reviewed, open access journal dedicated to advancing clinical and preclinical research. Our Editorial Board and staff are committed to delivering cutting-edge, timely, peer-reviewed articles spanning the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and impactful research articles, as well as reviews that are clinically significant and relevant to the full spectrum of medical disciplines. All full texts are archived in PubMed Central and indexed in SCIE (Web of Science), Scopus, PubMed, and other major databases. We invite you to submit your manuscript for publication, as well as join our community as a reviewer or reader online.

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).